Xiao Qin Lu
Director/Board Member chez FORTRESS BIOTECH, INC.
Fortune : 30 640 $ au 31/03/2024
Profil
Xiao Qin Lu is currently an Independent Director at Veru, Inc., a Director at Fortress Biotech, Inc., a Director at Inventia Healthcare Ltd., an Independent Director at Inventiva SA, and the Chief Operating Officer at Innovative Cellular Therapeutics Co., Ltd.
and Innovative Cellular Therapeutics, Inc. In the past, Dr. Lu has held positions such as Chief Executive Officer at Checkpoint Therapeutics, Inc., President, CEO, CFO & Director at Avenue Therapeutics, Inc., CFO, Executive VP & Head-Investor Relations at Fortress Biotech, Inc., and Research Analyst at Citigroup Global Markets, Inc. Dr. Lu has also served as an Independent Director at Veru, Inc. and as Vice President at Broadpoint.
Gleacher Securities.
Dr. Lu has an MBA from The Leonard N Stern School of Business, a doctorate from New York University School of Medicine, and an undergraduate degree from the College of Arts & Sciences (TN).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FORTRESS BIOTECH, INC.
0,06% | 27/03/2024 | 11 890 ( 0,06% ) | 23 780 $ | 31/03/2024 |
VERU INC
0,01% | 16/01/2024 | 9 800 ( 0,01% ) | 6 860 $ | 31/03/2024 |
Postes actifs de Xiao Qin Lu
| Sociétés | Poste | Début |
|---|---|---|
| INVENTIVA | Director/Board Member | 28/05/2018 |
| VERU INC. | Director/Board Member | 14/05/2021 |
| FORTRESS BIOTECH, INC. | Director/Board Member | 14/12/2022 |
Innovative Cellular Therapeutics Co., Ltd.
 Innovative Cellular Therapeutics Co., Ltd. BiotechnologyHealth Technology Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then. | Chief Operating Officer | - |
Inventia Healthcare Ltd.
 Inventia Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Inventia Healthcare Ltd. engages in the development and manufacture of pharmaceutical formulations. It caters anti-diabetic, gastrointestinal, CVC, CNS and musculoskeletal therapeutic areas. The company was founded by Janak Shah and Maya Shah in 1985 and is headquartered in Mumbai, India. | Director/Board Member | 01/01/2018 |
| Innovative Cellular Therapeutics, Inc. | Chief Operating Officer | 01/04/2022 |
Anciens postes connus de Xiao Qin Lu
| Sociétés | Poste | Fin |
|---|---|---|
| AVENUE THERAPEUTICS, INC. | Chief Executive Officer | 31/03/2022 |
| VERU INC. | Director/Board Member | 26/03/2019 |
| FORTRESS BIOTECH, INC. | Director of Finance/CFO | 26/06/2017 |
| ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Xiao Qin Lu
| The Leonard N Stern School of Business | Masters Business Admin |
| College of Arts & Sciences (TN) | Undergraduate Degree |
| New York University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| VERU INC. | Health Technology |
| FORTRESS BIOTECH, INC. | Health Technology |
| CHECKPOINT THERAPEUTICS, INC. | Health Technology |
| AVENUE THERAPEUTICS, INC. | Health Technology |
| INVENTIVA | Health Technology |
| Entreprise privées | 7 |
|---|---|
Citigroup Global Markets, Inc. (Broker)
 Citigroup Global Markets, Inc. (Broker) Investment Banks/BrokersFinance Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis. | Finance |
Broadpoint.Gleacher Securities
 Broadpoint.Gleacher Securities Investment Banks/BrokersFinance Broadpoint.Gleacher Securities, formerly Broadpoint Capital, Inc. is an independent, institutional investment banking, sales and trading boutique headquartered in New York City. They were also previously known as First Albany Capital, Inc. The firm is a subsidiary of Broadpoint Securities Group, Inc. (Nasdaq: BPSG), formerly known as First Albany Cos., Inc. They have additional offices in Boston, Chicago, Denver, San Francisco, Bonita Springs, Florida, Glen Allen, Virginia, Roseland, New Jersey and St. Louis, Missouri. Broadpoint.Gleacher follows a range of fixed-income securities and provides proprietary views and analysis on credit fundamentals and trading dynamics. They focus on investment grade, high yield and convertible securities in the following sectors: consumer, building materials, financials, gaming / leisure, healthcare, homebuilding, industrials, mining, packaging, paper/forest products, power/energy, technology/media/telecommunications and transportation. | Finance |
Lehman Brothers Global Asset Management
 Lehman Brothers Global Asset Management Investment Banks/BrokersFinance Part of Franklin Resources, Inc., Lehman Brothers Global Asset Management is an American asset management company. The private company is based in NY. Lehman Brothers Global Asset Management was acquired by Legg Mason, Inc., a subsidiary of Franklin Resources, Inc. from Lehman Brothers Holdings, Inc. on February 13, 1996 for $10 million. | Finance |
Lazard Asset Management LLC
 Lazard Asset Management LLC Investment ManagersFinance Lazard Asset Management LLC (LAM) is a SEC-registered investment advisor headquartered in New York City. The firm was founded in 1970 and is a wholly-owned subsidiary of Lazard Frères & Co. LLC, ultimately held by Lazard Ltd. (NYSE: LAZ). LAM provides investment advisory services to a variety of clients. | Finance |
Inventia Healthcare Ltd.
Inventia Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Inventia Healthcare Ltd. engages in the development and manufacture of pharmaceutical formulations. It caters anti-diabetic, gastrointestinal, CVC, CNS and musculoskeletal therapeutic areas. The company was founded by Janak Shah and Maya Shah in 1985 and is headquartered in Mumbai, India. | Health Technology |
Innovative Cellular Therapeutics Co., Ltd.
Innovative Cellular Therapeutics Co., Ltd. BiotechnologyHealth Technology Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then. | Health Technology |
| Innovative Cellular Therapeutics, Inc. |
